JAMES N INGLE, M.D.
Osteopathic Medicine at 1 St, Rochester, MN
License number
Minnesota 22613
Category
Osteopathic Medicine
Type
Medical Oncology
Address
Address
200 1St St SW, Rochester, MN 55905
Phone
(507) 284-2511
Organization information
See more information about JAMES N INGLE at bizstanding.comMayo Clinic - James N Ingle MD
200 1 St SW #W4, Rochester, MN 55905
Categories:
Physicians & Surgeons
Phone:
(507) 284-2511 (Phone)
Professional information
Dr. James N Ingle, Rochester MN - MD (Doctor of Medicine)
Specialties:
Oncology, Medical Oncology
Address:
Mayo Clinic
200 1St St SW, Rochester 55905
(507) 284-2511 (Phone)
200 1St St SW, Rochester 55905
(507) 284-2511 (Phone)
Certifications:
Internal Medicine, 1974, Medical Oncology, 1975
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Johns Hopkins University School Of Medicine
Graduated: 1971
Johns Hopkins Hospital
Graduated: 1972
National Institutes Of Health Clinical Center
Graduated: 1975
Johns Hopkins University School Of Medicine
Graduated: 1971
Johns Hopkins Hospital
Graduated: 1972
National Institutes Of Health Clinical Center
Graduated: 1975
Assessing Outcomes For Breast Cancer Patients Treated With Tamoxifen
US Patent:
2009020, Aug 20, 2009
Filed:
Dec 8, 2006
Appl. No.:
12/096723
Inventors:
Matthew P. Goetz - Rochester MN, US
James N. Ingle - Rochester MN, US
Richard M. Weinshilboum - Rochester MN, US
Fergus J. Couch - Rochester MN, US
Matthew M. Ames - Rochester MN, US
James N. Ingle - Rochester MN, US
Richard M. Weinshilboum - Rochester MN, US
Fergus J. Couch - Rochester MN, US
Matthew M. Ames - Rochester MN, US
International Classification:
C12Q 1/68
US Classification:
435 6
Abstract:
This document provides methods and materials related to assessing the likely outcome for mammals (e.g., humans) with cancer (e.g., breast cancer). For example, methods and materials that involve assessing a breast cancer patient's cytochrome P450, family 2, subfamily D, polypeptide 6 (CYP2D6) genotype to determine the likelihood of the beast cancer patient to experience breast cancer relapse or death are provided. Methods and materials that involve assessing the likelihood that a breast cancer patient being treated with tamoxifen will experience side effects such as hot flashes also are provided.
Medical Oncologist At Mayo Clinic
Position:
Medical Oncologist at Mayo Clinic
Location:
Rochester, Minnesota Area
Industry:
Hospital & Health Care
Work:
Mayo Clinic
-
Medical Oncologist
Assessing And Treating Breast Cancer Patients
US Patent:
2011013, Jun 9, 2011
Filed:
Aug 19, 2009
Appl. No.:
13/059590
Inventors:
Matthew P. Goetz - Rochester MN, US
James N. Ingle - Rochester MN, US
Vera J. Suman - Saint Charles MN, US
Matthew M. Ames - Rochester MN, US
Carol Reynolds - Rochester MN, US
James N. Ingle - Rochester MN, US
Vera J. Suman - Saint Charles MN, US
Matthew M. Ames - Rochester MN, US
Carol Reynolds - Rochester MN, US
International Classification:
A61K 31/138, C12Q 1/02, C12Q 1/68, G01N 33/574, A61P 35/00
US Classification:
514648, 435 29, 435 611, 435 723
Abstract:
This document provides methods and materials related to assessing and treating breast cancer patients. For example, methods and materials that involve assessing a breast cancer patient to determine whether the patient has (1) cancer cells that over express HER-2 polypeptides or comprise a HER-2 amplification and (2) at least an intermediate CYP2D6 metabolizer status are provided.
Assessing Outcomes For Breast Cancer Patients
US Patent:
2010024, Sep 30, 2010
Filed:
May 18, 2007
Appl. No.:
12/301258
Inventors:
Matthew P. Goetz - Rochester MN, US
James N. Ingle - Rochester MN, US
Fergus J. Couch - Rochester MN, US
Matthew M. Ames - Rochester MN, US
James N. Ingle - Rochester MN, US
Fergus J. Couch - Rochester MN, US
Matthew M. Ames - Rochester MN, US
Assignee:
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH - Rochester MN
International Classification:
C12Q 1/68
US Classification:
435 6
Abstract:
This document provides methods and materials related to assessing the likely outcome for mammals (e.g., humans) with cancer (e.g., breast cancer). For example, methods and materials for using the ratio of HOXB13 polypeptide expression to IL-17BR polypeptide expression, CYP2D6 genotype, medication history, or combinations thereof to determine the likelihood of a breast cancer patient to experience breast cancer relapse or death are provided.
Assessing Outcomes For Breast Cancer Patients
US Patent:
2009032, Dec 31, 2009
Filed:
Dec 8, 2006
Appl. No.:
12/096713
Inventors:
Matthew P. Goetz - Rochester MN, US
Fergus J. Couch - Rochester MN, US
James N. Ingle - Rochester MN, US
Vera J. Suman - St. Charles MN, US
Fergus J. Couch - Rochester MN, US
James N. Ingle - Rochester MN, US
Vera J. Suman - St. Charles MN, US
International Classification:
A61B 5/00
US Classification:
600300
Abstract:
This document provides methods and materials related to assessing the likely outcome for mammals (e.g., humans) with cancer (e.g., breast cancer). For example, methods and materials for using the ratio of HOXB13 polypeptide expression to IL-17BR polypeptide expression to determine the likelihood of a breast cancer patient to experience breast cancer relapse or death are provided.
James N Ingle, Rochester MN
Specialties:
Oncologist
Address:
200 1St St Sw, Rochester, MN 55905
Education:
Johns Hopkins University, School of Medicine - Doctor of Medicine
National Institutes of Health-Clinical Center - Fellowship - Oncology (Internal Medicine)
National Institutes of Health-Clinical Center - Fellowship - Oncology (Internal Medicine)
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine, American Board of Internal Medicine Sub-certificate in Oncology (Internal Medicine)
James Ingle, Rochester MN
Work:
Mayo Medical School
200 1St St SW, Rochester, MN 55905
200 1St St SW, Rochester, MN 55905